Laser Therapy in Women With Lichenoid Disorders
Key facts
- Who runs it
- Medical University of Graz
- Where
- Austria1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 40 people enrolled
- Started
- 17 Nov 2020
- Ended
- 13 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Laser
- Placebolaser
- Record updated
- 13 May 2025
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- women age >18 years
- diagnosed with LD (VLS or LP histologically proven)
- Clinical LS score ≥ 4 based on the score of Günthert et al. [1]
- Normal Pap-smear within 24 months
- negative clinical and microscopic evaluation of vaginal fluid
- Negative test for STD (sexually transmitted diseases) pathogens (chlamydia, gonorrhea, genital mycoplasma and trichomonas) if symptomic including abdominal pain or abnormal vaginal fluid
- Good German language skills
- written informed consent
- preceding local corticoid therapy of at least 12 weeks according to the current guideline for LD
Who cannot take part
- patients who have undergone any kind of organ transplantation in the last three years
- any vulvar/ vaginal infection
- genital malignant disease
- allergy to topical anaesthesia
- connective tissue disease
- History of transvaginal mesh implant (excluding sling or sacrocolpopexy mesh)
- patients with renal, hepatic or pulmonary-cardiovascular failure
- women with contraindications for the use of laser on the skin
- pregnancy
- presence of vulvar pathology (other than lichen)
- immunocompromised women
- swollen lymph nodes
- keloid formation
- Patients with a legal guardian
- Body Mass Index > 35 kg/m²
- Coagulopathy
- patients using anticoagulants
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Primary aim of the trial is to compare improvement of lichen symptoms according to a composite VAS scale (burning, itching and pain) between women with vulvovaginal laser therapy vs. sham laser therapy at three months.
The 2 groups in the trial
- LaserExisting treatment, for comparison
Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia. Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions.
- Placebo LaserPlacebo, for comparison
Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the "normal" probe. The treating physician will not be aware of the study allocation and the type of probe in use.
Treatment: Placebolaser
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Laser Therapy in Women With Lichenoid Disorders: A Randomized Controlled Trial
- Record updated
- 13 May 2025